La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

La industria farmacéutica niega el acceso a medicamentos básicos a millones de personas y socava su propio futuro, debido a la negativa de las compañías a cambiar sus estrategias de negocio en los mercados de los países en vías de desarrollo, según alerta Oxfam Internacional...El informe "Invertir en la vida. Cómo lograr el acceso a medicamentos esenciales a través de prácticas empresariales responsables" pone la lupa en las 12 principales compañías farmacéuticas mundiales. [se refiere a Abbott, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis y Wyeth]

Linha do tempo

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Fev 2008

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

19 Dez 2007

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

18 Dez 2007

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

18 Dez 2007

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Data:

12 Dez 2007

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Dez 2007

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Dez 2007

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Dez 2007

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Dez 2007

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Dez 2007

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Dez 2007

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
Oxfam report "Investing for Life": Company responses

Data:

12 Dez 2007

Tipo de conteúdo:

Artigo

Idiomas disponíveis: English
La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Data:

27 Nov 2007

Tipo de conteúdo:

Artigo

Idiomas disponíveis: español
Oxfam says top drug companies focusing on patents, not poor

Data:

26 Nov 2007

Tipo de conteúdo:

Artigo

Idiomas disponíveis: English
L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Data:

23 Nov 2007

Tipo de conteúdo:

Artigo

Idiomas disponíveis: français
Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Data:

12 Nov 2007

Tipo de conteúdo:

Resposta da empresa

Idiomas disponíveis: English
[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices

Data:

1 Nov 2007

Tipo de conteúdo:

Artigo

Idiomas disponíveis: English

Veja a história completa

Carregar mais Ver menos

Business & Human Rights
Resource Centre

Centro de Informação sobre Empresas e Direitos Humanos

Esta página não está disponível em Português e está sendo exibida em Spanish

La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Linha do tempo

Response by Sanofi-Aventis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Wyeth (part of Pfizer) did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Johnson & Johnson: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Abbott Laboratories: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Merck: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices"

Response by Novartis: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by AstraZeneca: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Eli Lilly did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Response by Pfizer: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Bristol-Myers Squibb did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Roche did not respond to: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

Oxfam report "Investing for Life": Company responses

La industria farmacéutica socava su futuro mientras impide el acceso de millones de personas a medicamentos básicos

Oxfam says top drug companies focusing on patents, not poor

L’industrie pharmaceutique met en péril son propre avenir en empêchant des millions de personnes pauvres d’avoir accès aux médicaments

Response by GlaxoSmithKline: Oxfam report "Investing for Life" says drug companies not doing enough to provide access to medicines for the poor - makes recommendations for "responsible business practices".

[PDF] Investing for life - Meeting poor people’s needs for access to medicines through responsible business practices